Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article Report
  • Published:

Author’s response to “Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?”

Nature Clinical Practice Endocrinology & Metabolism volume 3, page E2 (2007)Cite this article

Access through your institution
Buy or subscribe

Response to: Edelman SV et al. (2007) Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab [10.1038/ncpendmet0506]

To read Monnier’s original commentary, click here

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Monnier L (2007) Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab 3: 332–333

    Article  CAS  Google Scholar 

  2. Edelman S et al. (2006) A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 29: 2189–2195

    Article  CAS  Google Scholar 

  3. Marrero DG et al. (2007) Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care 30: 210–216

    Article  CAS  Google Scholar 

  4. American Diabetes Association (2007) Standards of medical care in diabetes–2007. Diabetes Care 30 (suppl 1): S4–S41

Download references

Author information

Author notes

  1. Department of Metabolic Diseases, Lapeyronie Hospital, 371 Avenue du Doyen G Giraud, 34295 Montpellier Cedex 5, France l-monnier@chu-montpellier.fr

Authors and Affiliations

  1. Department of Metabolic Diseases, Lapeyronie Hospital, 371 Avenue du Doyen G Giraud, Montpellier, 34295, Cedex 5, France

    Louis Monnier

Authors
  1. Louis Monnier
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Monnier, L. Author’s response to “Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?”. Nat Rev Endocrinol 3, E2 (2007). https://doi.org/10.1038/ncpendmet0507

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpendmet0507

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing